201 related articles for article (PubMed ID: 19778326)
1. Detection of oxidized low-density lipoproteins in gingival crevicular fluid from dental patients.
Sakiyama Y; Kato R; Inoue S; Suzuki K; Itabe H; Yamamoto M
J Periodontal Res; 2010 Apr; 45(2):216-22. PubMed ID: 19778326
[TBL] [Abstract][Full Text] [Related]
2. The apolipoprotein B concentration in gingival crevicular fluid increases in patients with diabetes mellitus.
Noguchi E; Kato R; Ohno K; Mitsui A; Obama T; Hirano T; Itabe H; Yamamoto M
Clin Biochem; 2014 Jan; 47(1-2):67-71. PubMed ID: 24095848
[TBL] [Abstract][Full Text] [Related]
3. Changes in apolipoprotein B and oxidized low-density lipoprotein levels in gingival crevicular fluids as a result of periodontal tissue conditions.
Ishizuka M; Kato R; Moriya Y; Noguchi E; Koide Y; Inoue S; Itabe H; Yamamoto M
J Periodontal Res; 2017 Jun; 52(3):594-602. PubMed ID: 28233905
[TBL] [Abstract][Full Text] [Related]
4. Locally produced anti-phosphorylcholine and anti-oxidized low-density lipoprotein antibodies in gingival crevicular fluid from aggressive periodontitis patients.
Schenkein HA; Berry CR; Burmeister JA; Brooks CN; Best AM; Tew JG
J Periodontol; 2004 Jan; 75(1):146-53. PubMed ID: 15025226
[TBL] [Abstract][Full Text] [Related]
5. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women?
Wu T; Willett WC; Rifai N; Shai I; Manson JE; Rimm EB
J Am Coll Cardiol; 2006 Sep; 48(5):973-9. PubMed ID: 16949489
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins.
Radulescu L; Stancu C; Antohe F
Med Sci Monit; 2004 Jul; 10(7):BR207-14. PubMed ID: 15232494
[TBL] [Abstract][Full Text] [Related]
7. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects.
Shoji T; Nishizawa Y; Fukumoto M; Shimamura K; Kimura J; Kanda H; Emoto M; Kawagishi T; Morii H
Atherosclerosis; 2000 Jan; 148(1):171-7. PubMed ID: 10580183
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study.
Koskinen J; Magnussen CG; Würtz P; Soininen P; Kangas AJ; Viikari JS; Kähönen M; Loo BM; Jula A; Ahotupa M; Lehtimäki T; Ala-Korpela M; Juonala M; Raitakari OT
Eur J Prev Cardiol; 2012 Dec; 19(6):1296-303. PubMed ID: 21960651
[TBL] [Abstract][Full Text] [Related]
9. Oxidized low-density lipoprotein (oxLDL) plasma levels and oxLDL to LDL ratio - are they real oxidative stress markers in dialyzed patients?
Pawlak K; Mysliwiec M; Pawlak D
Life Sci; 2013 Mar; 92(4-5):253-8. PubMed ID: 23295961
[TBL] [Abstract][Full Text] [Related]
10. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
Holvoet P; Donck J; Landeloos M; Brouwers E; Luijtens K; Arnout J; Lesaffre E; Vanrenterghem Y; Collen D
Thromb Haemost; 1996 Nov; 76(5):663-9. PubMed ID: 8950769
[TBL] [Abstract][Full Text] [Related]
11. The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions.
Itabe H; Kato R; Sawada N; Obama T; Yamamoto M
Curr Med Chem; 2019; 26(9):1576-1593. PubMed ID: 29521196
[TBL] [Abstract][Full Text] [Related]
12. Gingival crevicular fluid levels of calprotectin and myeloperoxidase during therapy for generalized aggressive periodontitis.
Kaner D; Bernimoulin JP; Kleber BM; Heizmann WR; Friedmann A
J Periodontal Res; 2006 Apr; 41(2):132-9. PubMed ID: 16499716
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
[TBL] [Abstract][Full Text] [Related]
14. Immunological detection of large oxidized lipoproteins in hypertriglyceridemic serum.
Sakurai T; Wada N; Takahashi Y; Ichikawa A; Ikuta A; Furumaki H; Hui SP; Jin S; Takeda S; Fuda H; Fujikawa M; Shimizu C; Nagasaka H; Furukawa H; Kobayashi S; Chiba H
Ann Clin Biochem; 2013 Sep; 50(Pt 5):465-72. PubMed ID: 23858503
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
16. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody.
Itabe H; Yamamoto H; Imanaka T; Shimamura K; Uchiyama H; Kimura J; Sanaka T; Hata Y; Takano T
J Lipid Res; 1996 Jan; 37(1):45-53. PubMed ID: 8820101
[TBL] [Abstract][Full Text] [Related]
17. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
[TBL] [Abstract][Full Text] [Related]
18. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease.
Andican G; Seven A; Uncu M; Cantaşdemir M; Numan F; Burçak G
Scand J Clin Lab Invest; 2008; 68(6):473-8. PubMed ID: 18609113
[TBL] [Abstract][Full Text] [Related]
19. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
Turk Z; Mrzljak V; Turk N; Metelko Z
Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease.
Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC
Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
